Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3470490 | 0.75 | HRH4 (0.42) | HRH4DYRK1ACLK1DRD2DRD4 | |
| SCHEMBL12777861 | 0.75 | HRH4 (0.42) | HRH4DYRK1ACLK1DRD2DRD4 | |
| SCHEMBL4400860 | 0.75 | HRH4 (0.45) | HRH4DYRK1ACLK1DRD2DRD4 | |
| SCHEMBL3524087 | 0.75 | PDE3B (0.45) | HRH4DYRK1ACLK1DRD2DRD4 | |
| SCHEMBL5315034 | 0.73 | NPC1 (0.62) | DYRK1ACLK1PDE3BPDE3A | |
| SCHEMBL12196978 | 0.71 | DRD2 (0.44) | HRH4DYRK1ACLK1DRD2DRD4 | |
| SCHEMBL12223303 | 0.71 | DRD2 (0.47) | HRH4DYRK1ACLK1DRD2DRD4 | |
| SCHEMBL31361318 | 0.71 | HRH4 (0.39) | HRH4DYRK1ACLK1DRD2DRD4 | |
| SCHEMBL22607307 | 0.71 | HRH4 (0.42) | HRH4DYRK1ACLK1DRD2DRD4 | |
| SCHEMBL9966056 | 0.71 | DRD2 (0.47) | HRH4DYRK1ACLK1DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115569-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | LARIO THERAPEUTICS LTD (GB) | 2025-04-10 | — | — | US | disclosed |
| EP-4436955-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | Lario Therapeutics Limited (GB) | 2024-10-02 | — | — | EP | disclosed |
| CN-118317950-A | Sulfonamide compounds for the treatment of neurological disorders | 拉里奥治疗有限公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2023094830-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | LARIO THERAPEUTICS LIMITED (GB) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023094830-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | LARIO THERAPEUTICS LIMITED (GB) | 2023-06-01 | — | — | WO | disclosed |
| US-20230087118-A1 | IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. | 2023-03-23 | — | — | US | disclosed |
| US-9559310-B2 | Compound with electron injection and/or electron transport capabilities and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-01-31 | — | — | US | disclosed |
| WO-2014117318-A1 | NOVEL TRIAZOLE ANTIFUNGAL COMPOUNDS, AND PHARMACEUTICAL COMPOSITION, PREPARATION METHOD, AND APPLICATION THEREOF | 中国科学院上海药物研究所 (CN) | 2014-08-07 | — | — | WO | disclosed |
| US-20140014925-A1 | NOVEL COMPOUND WITH ELECTRON INJECTION AND/OR ELECTRON TRANSPORT CAPABILITIES AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2014-01-16 | — | — | US | disclosed |
| WO-2005085252-A1 | IMIDAZO ‘1,2-A’ PYRAZINE COMPOUNDS WHICH INTERACT WITH PROTEIN KINASES | BIOFOCUS DISCOVERY LIMITED (GB) | 2005-09-15 | — | — | WO | disclosed |
| US-4408047-A | ADRENERGIC BLOCKING | MERCK & CO., INC. (US) | 1983-10-04 | — | — | US | disclosed |
| US-4330543-A | AS ADRENERGIC BLOCKING AGENTS | MERCK & CO., INC. (US) | 1982-05-18 | — | — | US | disclosed |
| US-4233301-A | ADRENERGIC BLOCKING AGENTS | MERCK & CO., INC. (US) | 1980-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115569-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | CACNA1A, CACNA1E, CACNA1S | HRH4 1684/4885DYRK1A 973/4885CLK1 3353/4885 |
| US-20230087118-A1 | IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | IRAK4, IRAK2, IRAK1 | HRH4 724/4885DYRK1A 841/4885CLK1 3412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.